Bortezomib in the treatment of cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 1, Issue 3, 2006, Pages 397-403

  Roccaro, Aldo M ^a   Vacca, Angelo ^a   Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Anti tumor activity; Bortezomib; Proteasome inhibition

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; PROTEASOME; PYRAZINE DERIVATIVE;

ANIMAL; APOPTOSIS; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; NEOPLASM; PATENT; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PATENTS AS TOPIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SIGNAL TRANSDUCTION;

EID: 39049173144     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489206778776925     Document Type: Article

References (53)

1. Nussbaum AK, Dick TP, Keilholz W, et al. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci USA 1998; 95: 12504.
2. Zwickl P, Voges D, Baumeister W. The proteasome: a macromolecular assembly designed for controlled proteolysis. Trans R Soc Lond B Biol Sci 1999; 354: 1501.
3. Kisselev AF, Goldberg AL. Proteasome inhibitor: from research tools to drug candidates. Chem Biol 2001; 8: 739.
4. Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998; 8: 333.
5. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639.
6. Gilmore TD, Koedood M, Piffat KA, et al. Rel/NFkappaB/IkappaB proteins and cancer. Oncogene 1996; 13: 1367.
7. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications. Blood 2002; 99: 4079.
8. Karin M, Delhase M, The I. kappa B kinase (IKK) and NF-kappa B: Key elements of proinflammatory signalling. Semin Immunol 2000; 12: 85.
9. Gardner RC, Assinder SJ, Christie G, et al. Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cells. Biochem J 2000; 346: 447.
10. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-B activity. Annu Rev Immunol 2000; 18: 621.
11. Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications. Oncogene 2001; 20: 4519.
12. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996; 87: 1104.
13. Hazlehurst LA, Damiano JS, Buyuksal I, et al. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000; 19: 4319.
14. Hazlehurst LA, Dalton WS. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev 2001; 20: 43.
15. Dalton WS, Bergsagel PL, Kuehl WM, et al. Multiple myeloma, in Schechter GP, Broudy VB, Williams ME (eds): Hematology 2001. Washington, DC, American Society of Hematology, pp 157-177.
16. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7: 1419.
17. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374.
18. Hideshima T, Richardson P, Chauhan D, et al. The proteaosme inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma. Cancer Res 2001; 61: 3071.
19. Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001; 82: 110.
20. Ling YH, Liebes L, Mg B, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorilation and cleavage in association with GM-2 phase arrest and apoptosis. Mol Cancer Ther 2002; 1:841.
21. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341. Blood 2003; 101:1530.
22. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic implications. Blood 2002; 99: 4525.
23. Breitschopf K, Zeiher AM, Dimmeler S. Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J Biol Chem 2000; 275: 21648.
24. Li B, Dou QP. Bax degradation by the ubiquitin/proteasomedependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 2000; 97: 3850.
25. Drexler HC, Risau W, Konerding MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000; 14: 65.
26. Oikawa T, Sasaki T, Nakamura M, et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998; 246: 243.
27. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62:4996.
28. Roccaro AM, Hideshima T, Raje N, et al. Bortezomib targets multiple myeloma endothelial cells. Cancer Res. 2006; 1: 184.
29. Millenium Pharmaceuticals: VELCADE (Bortezomib) for injection: Prescribing Information. Cambridge, MA, Millenium Pharmaceuticals, Inc, 2003.
30. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609.
31. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20:4420.
32. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8:2505.
33. Lee S, Richardson P, Barlogie B, et al. Quality-of-life (QOL) and clinical benefit assessment in patients with relapsed and refractory multiple myeloma (MM) treated with bortezomib. Proc Am Soc Clin Oncol 2003; 22: 582. (abstr 2339).
34. Berenson JR, Jagannath S, Barlogie B, et al. Experience with long-term therapy using the proteasome inhibitor, bortezomib, in advanced multiple myeloma (MM). Proc Am Soc Clin Oncol 2003; 22: 581 (abstr 2337).
35. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high dose dexametasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487.
36. Adams J, Palombella VJ, Sausville EA. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615.
37. Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003; 9: 1145.
38. Williams S, Pettaway C, Song R, et al. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003; 2: 835.
39. Albanell J, Baselga J, Guix M, et al. Phase I study of bortezomib in combination with docetaxel in anthracycline-pretreated advanced breast cancer. Proc Am Soc Clin Oncol 2003; 22: 16.
40. Davis NB, Taber DA, Ansari R. H, et al. A phase II trial of PS-341 in patients with renal cell cancer. Proc Am Soc Clin Oncol 2003; 22: 386 (abstr 1551).
41. Pink M, Pien CS, Worland P, et al. PS-341 enhances chemotherapeutic effect in human xenograft models. Proc Am Assoc Cancer Res 2002; 43: 158.
42. Cheson BD. New drug development in non-Hodgkin lymphomas. Curr Oncol Rep 2001; 3: 250.
43. Goy AH, East K, Mesina O, et al. Report of a phase II study of proteasome inhibitor bortezomib in patients with relapsed or refractory indolent and aggressive B-cell lymphomas. Proc Am Soc Clin Oncol 2003; 22: 570 (abstr 2291).
44. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphomas. Proc Am Soc Clin Oncol 2003; 22: 566 (abstr 2277).
45. Drucker BJ, Schwartz L, Bacik J, et al. Phase II trial of PS-341 shows response in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2003; 22: 386 (abstr 1550).
46. Maki RG, Kraft A, Demetri GD, et al. A phase II multicenter study of proteasome inhibitor PS-341 (LDP-341, bortezomib) for untreated recurrent or metastatic soft tissue sarcoma (STS); CTEP study 1757. Proc Am Soc Clin Oncol 2003; 22: 819 (abstr 3291).
47. Stevenson J, Nho CW, Schick J, et al. Phase II clinical/pharmacodynamic trial of the proteasome inhibitor PS-341 in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22: 202 (abstr 810).
48. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 2005; 90:1655.
49. Cortes J, Thomas D, Koller C, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004; 10: 3371.
50. Mundy, G.R.: US20026492333 (2002).
51. Bhide, R.S., Ruel, R., Thibault, C., L'Heureux, A.: US20056969717 (2005).
52. Bhide, R.S., Borzilleri, R.M.: US6951859 (2005).
53. Bhide, R.S., Cai, Z.-W., Qian, L., Barbosa, S.: US20056869952 (2005).